Recent Analysts’ Ratings Changes for Immuneering (IMRX)

Several brokerages have updated their recommendations and price targets on shares of Immuneering (NASDAQ: IMRX) in the last few weeks:

• 12/1/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – Immuneering was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/13/2025 – Immuneering had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
• 10/31/2025 – Immuneering was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 10/31/2025 – Immuneering is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $15.00 price target on the stock.
• 10/29/2025 – Immuneering was given a new $12.00 price target on by analysts at Mizuho.
• 10/8/2025 – Immuneering had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other news, Director Peter Feinberg purchased 7,500 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were bought at an average cost of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the purchase, the director directly owned 156,766 shares of the company’s stock, valued at approximately $1,045,629.22. This trade represents a 5.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought a total of 20,800 shares of company stock worth $143,754 over the last ninety days. Company insiders own 22.90% of the company’s stock.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.